FibroBiologics (FBLG) Competitors

$1.05 -0.03 (-2.78%)

Closing price 04:00 PM Eastern

Extended Trading

$1.08 +0.02 (+2.38%)

As of 07:24 PM Eastern

FBLG vs. ANEB, XCUR, QNCX, QNTM, and KTTA

Should you buy FibroBiologics stock or one of its competitors? MarketBeat compares FibroBiologics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with FibroBiologics include Anebulo Pharmaceuticals (ANEB), Exicure (XCUR), Quince Therapeutics (QNCX), Quantum Biopharma (QNTM), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical products" industry.

How does FibroBiologics compare to Anebulo Pharmaceuticals?

FibroBiologics (NASDAQ:FBLG) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, FibroBiologics had 5 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 5 mentions for FibroBiologics and 0 mentions for Anebulo Pharmaceuticals. FibroBiologics' average media sentiment score of 0.47 beat Anebulo Pharmaceuticals' score of 0.00 indicating that FibroBiologics is being referred to more favorably in the media.

Company	Overall Sentiment
FibroBiologics	Neutral
Anebulo Pharmaceuticals	Neutral

FibroBiologics presently has a consensus price target of $74.00, indicating a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts clearly believe FibroBiologics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Anebulo Pharmaceuticals' return on equity of -74.57% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

FibroBiologics has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.93, indicating that its stock price is 293% less volatile than the broader market.

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 9.3% of FibroBiologics shares are held by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

FibroBiologics and Anebulo Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Exicure?

FibroBiologics (NASDAQ:FBLG) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

42.8% of Exicure shares are held by institutional investors. 9.3% of FibroBiologics shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, FibroBiologics had 2 more articles in the media than Exicure. MarketBeat recorded 5 mentions for FibroBiologics and 3 mentions for Exicure. Exicure's average media sentiment score of 0.93 beat FibroBiologics' score of 0.47 indicating that Exicure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has higher revenue and earnings than FibroBiologics. Exicure is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A
Exicure	$500K	36.18	-$4.95M	-$0.77	N/A

FibroBiologics presently has a consensus price target of $74.00, indicating a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher probable upside, research analysts clearly believe FibroBiologics is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Exicure has a beta of 3.62, indicating that its share price is 262% more volatile than the broader market.

Exicure's return on equity of -138.71% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FibroBiologics	N/A	-767.07%	-195.56%
Exicure	N/A	-138.71%	-62.76%

Summary

Exicure beats FibroBiologics on 9 of the 13 factors compared between the two stocks.

How does FibroBiologics compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Quince Therapeutics' return on equity of -372.88% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
FibroBiologics	N/A	-767.07%	-195.56%

Quince Therapeutics presently has a consensus price target of $65.00, indicating a potential upside of 5,552.17%. FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FibroBiologics had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 5 mentions for FibroBiologics and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 1.35 beat FibroBiologics' score of 0.47 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

30.8% of Quince Therapeutics shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by company insiders. Comparatively, 9.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Quince Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

FibroBiologics is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

Summary

Quince Therapeutics and FibroBiologics tied by winning 6 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Quantum Biopharma?

Quantum Biopharma (NASDAQ:QNTM) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Quantum Biopharma is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

In the previous week, FibroBiologics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for Quantum Biopharma. Quantum Biopharma's average media sentiment score of 0.62 beat FibroBiologics' score of 0.47 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

FibroBiologics' return on equity of -767.07% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
FibroBiologics	N/A	-767.07%	-195.56%

Quantum Biopharma has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market.

FibroBiologics has a consensus price target of $74.00, indicating a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts plainly believe FibroBiologics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.2% of Quantum Biopharma shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by company insiders. Comparatively, 9.3% of FibroBiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

FibroBiologics beats Quantum Biopharma on 10 of the 12 factors compared between the two stocks.

How does FibroBiologics compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Pasithea Therapeutics' return on equity of -85.48% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pasithea Therapeutics	N/A	-85.48%	-77.42%
FibroBiologics	N/A	-767.07%	-195.56%

Pasithea Therapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 284.57%. FibroBiologics has a consensus price target of $74.00, suggesting a potential upside of 6,947.62%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
FibroBiologics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, FibroBiologics had 3 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 5 mentions for FibroBiologics and 2 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat FibroBiologics' score of 0.47 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Pasithea Therapeutics	Very Positive
FibroBiologics	Neutral

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A
FibroBiologics	N/A	N/A	-$18.65M	-$6.93	N/A

23.9% of Pasithea Therapeutics shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by insiders. Comparatively, 9.3% of FibroBiologics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

Summary

FibroBiologics beats Pasithea Therapeutics on 6 of the 11 factors compared between the two stocks.

Get FibroBiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBLG vs. The Competition

Export

Metric	FibroBiologics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.63M	$3.39B	$6.34B	$12.47B
Dividend Yield	N/A	2.31%	2.80%	5.28%
P/E Ratio	N/A	10.27	17.27	22.75
Price / Sales	N/A	286.18	547.04	77.06
Price / Cash	N/A	124.05	43.04	56.01
Price / Book	2.10	6.63	9.83	6.91
Net Income	-$18.65M	$24.16M	$3.56B	$333.88M
7 Day Performance	-9.48%	3.88%	0.27%	0.01%
1 Month Performance	-31.82%	-3.02%	-0.98%	1.75%
1 Year Performance	-94.85%	68.84%	36.22%	32.67%

FibroBiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBLG FibroBiologics	3.613 of 5 stars	$1.05 -2.8%	$74.00 +6,947.6%	-93.5%	$5.63M	N/A	N/A	10	Gap Down
ANEB Anebulo Pharmaceuticals	N/A	$0.52 +13.0%	$3.00 +476.9%	-53.1%	$21.21M	N/A	N/A	4
XCUR Exicure	1.03 of 5 stars	$3.27 -3.3%	N/A	-70.2%	$20.84M	N/A	N/A	50	News Coverage Gap Down
QNCX Quince Therapeutics	2.7417 of 5 stars	$1.22 -2.0%	$65.00 +5,249.8%	-86.0%	$19.80M	N/A	N/A	60	News Coverage Positive News Earnings Report
QNTM Quantum Biopharma	0.2402 of 5 stars	$5.17 +2.2%	N/A	-16.4%	$19.75M	N/A	N/A	N/A	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBLG) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FibroBiologics (FBLG) Competitors

FBLG vs. ANEB, XCUR, QNCX, QNTM, and KTTA

How does FibroBiologics compare to Anebulo Pharmaceuticals?

Summary

How does FibroBiologics compare to Exicure?

Summary

How does FibroBiologics compare to Quince Therapeutics?

Summary

How does FibroBiologics compare to Quantum Biopharma?

Summary

How does FibroBiologics compare to Pasithea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

FibroBiologics (FBLG) Competitors

FBLG vs. ANEB, XCUR, QNCX, QNTM, and KTTA

How does FibroBiologics compare to Anebulo Pharmaceuticals?

Does the media favor FBLG or ANEB?

Do analysts rate FBLG or ANEB?

Which has preferable valuation and earnings, FBLG or ANEB?

Is FBLG or ANEB more profitable?

Which has more risk & volatility, FBLG or ANEB?

Do insiders and institutionals believe in FBLG or ANEB?

Summary

How does FibroBiologics compare to Exicure?

Do institutionals and insiders believe in FBLG or XCUR?

Does the media refer more to FBLG or XCUR?

Which has better valuation & earnings, FBLG or XCUR?

Do analysts rate FBLG or XCUR?

Which has more volatility and risk, FBLG or XCUR?

Is FBLG or XCUR more profitable?

Summary

How does FibroBiologics compare to Quince Therapeutics?

Is QNCX or FBLG more profitable?

Do analysts rate QNCX or FBLG?

Does the media refer more to QNCX or FBLG?

Do institutionals and insiders believe in QNCX or FBLG?

Which has more risk and volatility, QNCX or FBLG?

Which has preferable valuation and earnings, QNCX or FBLG?

Summary

How does FibroBiologics compare to Quantum Biopharma?

Which has preferable valuation and earnings, QNTM or FBLG?

Does the media refer more to QNTM or FBLG?

Is QNTM or FBLG more profitable?

Which has more risk and volatility, QNTM or FBLG?

Do analysts rate QNTM or FBLG?

Do institutionals and insiders believe in QNTM or FBLG?

Summary

How does FibroBiologics compare to Pasithea Therapeutics?

Is KTTA or FBLG more profitable?

Do analysts prefer KTTA or FBLG?

Does the media prefer KTTA or FBLG?

Which has higher earnings & valuation, KTTA or FBLG?

Do institutionals & insiders have more ownership in KTTA or FBLG?

Which has more risk and volatility, KTTA or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBLG vs. The Competition

FibroBiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools